nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—Progesterone Congeners—Medroxyprogesterone Acetate—uterine cancer	0.323	1	CiPCiCtD
Norethindrone—Progesterone—uterine cancer	0.214	1	CrCtD
Norethindrone—PGR—uterine cancer	0.102	1	CbGaD
Norethindrone—PGR—Medroxyprogesterone Acetate—uterine cancer	0.0339	0.238	CbGbCtD
Norethindrone—SHBG—Medroxyprogesterone Acetate—uterine cancer	0.0325	0.228	CbGbCtD
Norethindrone—PGR—Progesterone—uterine cancer	0.0224	0.157	CbGbCtD
Norethindrone—SHBG—Progesterone—uterine cancer	0.0215	0.151	CbGbCtD
Norethindrone—Stanozolol—Progesterone—uterine cancer	0.0111	0.0668	CrCrCtD
Norethindrone—Ethynodiol—Medroxyprogesterone Acetate—uterine cancer	0.0103	0.0621	CrCrCtD
Norethindrone—Nandrolone phenpropionate—Progesterone—uterine cancer	0.00956	0.0577	CrCrCtD
Norethindrone—Nandrolone decanoate—Progesterone—uterine cancer	0.00956	0.0577	CrCrCtD
Norethindrone—Norgestimate—Progesterone—uterine cancer	0.00896	0.0541	CrCrCtD
Norethindrone—Oxandrolone—Progesterone—uterine cancer	0.00896	0.0541	CrCrCtD
Norethindrone—Ethynodiol—Progesterone—uterine cancer	0.00896	0.0541	CrCrCtD
Norethindrone—Drospirenone—Medroxyprogesterone Acetate—uterine cancer	0.00871	0.0526	CrCrCtD
Norethindrone—Formestane—Progesterone—uterine cancer	0.008	0.0483	CrCrCtD
Norethindrone—Drospirenone—Progesterone—uterine cancer	0.00759	0.0459	CrCrCtD
Norethindrone—Levonorgestrel—Progesterone—uterine cancer	0.00662	0.04	CrCrCtD
Norethindrone—Danazol—Progesterone—uterine cancer	0.00611	0.0369	CrCrCtD
Norethindrone—Cortisone acetate—Medroxyprogesterone Acetate—uterine cancer	0.00591	0.0357	CrCrCtD
Norethindrone—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.00547	0.0384	CbGbCtD
Norethindrone—CYP3A7—Progesterone—uterine cancer	0.00547	0.0384	CbGbCtD
Norethindrone—Fluoxymesterone—Medroxyprogesterone Acetate—uterine cancer	0.00527	0.0318	CrCrCtD
Norethindrone—Cortisone acetate—Progesterone—uterine cancer	0.00515	0.0311	CrCrCtD
Norethindrone—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.00513	0.031	CrCrCtD
Norethindrone—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.00513	0.031	CrCrCtD
Norethindrone—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.005	0.0302	CrCrCtD
Norethindrone—Fluoxymesterone—Progesterone—uterine cancer	0.00459	0.0277	CrCrCtD
Norethindrone—Testosterone Propionate—Progesterone—uterine cancer	0.00447	0.027	CrCrCtD
Norethindrone—Testosterone—Medroxyprogesterone Acetate—uterine cancer	0.00445	0.0269	CrCrCtD
Norethindrone—Methyltestosterone—Progesterone—uterine cancer	0.00436	0.0263	CrCrCtD
Norethindrone—Hydrocortisone—Medroxyprogesterone Acetate—uterine cancer	0.00418	0.0253	CrCrCtD
Norethindrone—CYP3A5—Progesterone—uterine cancer	0.0041	0.0288	CbGbCtD
Norethindrone—Testosterone—Progesterone—uterine cancer	0.00388	0.0235	CrCrCtD
Norethindrone—Hydrocortisone—Progesterone—uterine cancer	0.00365	0.022	CrCrCtD
Norethindrone—CYP2C19—Progesterone—uterine cancer	0.00331	0.0232	CbGbCtD
Norethindrone—ABCB1—Progesterone—uterine cancer	0.00267	0.0187	CbGbCtD
Norethindrone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00241	0.0169	CbGbCtD
Norethindrone—PGR—corpus luteum—uterine cancer	0.00228	0.26	CbGeAlD
Norethindrone—ABCB1—Dactinomycin—uterine cancer	0.00212	0.0148	CbGbCtD
Norethindrone—CYP3A5—Etoposide—uterine cancer	0.00184	0.0129	CbGbCtD
Norethindrone—CYP3A4—Progesterone—uterine cancer	0.0016	0.0112	CbGbCtD
Norethindrone—ABCB1—Etoposide—uterine cancer	0.00119	0.00838	CbGbCtD
Norethindrone—SHBG—semen—uterine cancer	0.00119	0.135	CbGeAlD
Norethindrone—ABCB1—Doxorubicin—uterine cancer	0.000815	0.00572	CbGbCtD
Norethindrone—PGR—oviduct—uterine cancer	0.000785	0.0893	CbGeAlD
Norethindrone—CYP3A4—Etoposide—uterine cancer	0.000716	0.00502	CbGbCtD
Norethindrone—PGR—artery—uterine cancer	0.00052	0.0592	CbGeAlD
Norethindrone—CYP3A4—Doxorubicin—uterine cancer	0.000488	0.00342	CbGbCtD
Norethindrone—PGR—myometrium—uterine cancer	0.000251	0.0286	CbGeAlD
Norethindrone—PGR—epithelium—uterine cancer	0.000197	0.0224	CbGeAlD
Norethindrone—SHBG—endometrium—uterine cancer	0.000196	0.0223	CbGeAlD
Norethindrone—PGR—uterine cervix—uterine cancer	0.000195	0.0222	CbGeAlD
Norethindrone—PGR—smooth muscle tissue—uterine cancer	0.00019	0.0216	CbGeAlD
Norethindrone—PGR—decidua—uterine cancer	0.000186	0.0212	CbGeAlD
Norethindrone—SHBG—uterus—uterine cancer	0.000181	0.0206	CbGeAlD
Norethindrone—PGR—endometrium—uterine cancer	0.000177	0.0201	CbGeAlD
Norethindrone—PGR—uterus—uterine cancer	0.000163	0.0185	CbGeAlD
Norethindrone—SHBG—female reproductive system—uterine cancer	0.000162	0.0185	CbGeAlD
Norethindrone—SHBG—female gonad—uterine cancer	0.000148	0.0168	CbGeAlD
Norethindrone—SHBG—vagina—uterine cancer	0.000147	0.0167	CbGeAlD
Norethindrone—PGR—female reproductive system—uterine cancer	0.000146	0.0167	CbGeAlD
Norethindrone—PGR—female gonad—uterine cancer	0.000133	0.0152	CbGeAlD
Norethindrone—PGR—vagina—uterine cancer	0.000132	0.0151	CbGeAlD
Norethindrone—CYP3A5—uterine cervix—uterine cancer	0.000114	0.0129	CbGeAlD
Norethindrone—CYP3A5—renal system—uterine cancer	0.000106	0.0121	CbGeAlD
Norethindrone—CYP2C19—vagina—uterine cancer	9.77e-05	0.0111	CbGeAlD
Norethindrone—Affect lability—Progesterone—uterine cancer	9.16e-05	0.00222	CcSEcCtD
Norethindrone—Migraine—Progesterone—uterine cancer	9.16e-05	0.00222	CcSEcCtD
Norethindrone—Mood swings—Progesterone—uterine cancer	8.81e-05	0.00214	CcSEcCtD
Norethindrone—Purpura—Medroxyprogesterone Acetate—uterine cancer	8.75e-05	0.00212	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Medroxyprogesterone Acetate—uterine cancer	8.71e-05	0.00211	CcSEcCtD
Norethindrone—PGR—lymph node—uterine cancer	8.56e-05	0.00975	CbGeAlD
Norethindrone—Ethynodiol—PGR—uterine cancer	8.53e-05	0.0599	CrCbGaD
Norethindrone—Erythema nodosum—Epirubicin—uterine cancer	8.5e-05	0.00206	CcSEcCtD
Norethindrone—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	8.43e-05	0.00204	CcSEcCtD
Norethindrone—Breast disorder—Progesterone—uterine cancer	8.41e-05	0.00204	CcSEcCtD
Norethindrone—Affect lability—Medroxyprogesterone Acetate—uterine cancer	8.3e-05	0.00201	CcSEcCtD
Norethindrone—Migraine—Medroxyprogesterone Acetate—uterine cancer	8.3e-05	0.00201	CcSEcCtD
Norethindrone—Abdominal distension—Progesterone—uterine cancer	8.09e-05	0.00196	CcSEcCtD
Norethindrone—Norelgestromin—PGR—uterine cancer	8.06e-05	0.0566	CrCbGaD
Norethindrone—Allylestrenol—PGR—uterine cancer	8.06e-05	0.0566	CrCbGaD
Norethindrone—Mood swings—Medroxyprogesterone Acetate—uterine cancer	7.99e-05	0.00193	CcSEcCtD
Norethindrone—CYP3A4—renal system—uterine cancer	7.98e-05	0.00908	CbGeAlD
Norethindrone—Erythema nodosum—Doxorubicin—uterine cancer	7.86e-05	0.0019	CcSEcCtD
Norethindrone—ALB—lymph node—uterine cancer	7.85e-05	0.00894	CbGeAlD
Norethindrone—Desogestrel—PGR—uterine cancer	7.75e-05	0.0545	CrCbGaD
Norethindrone—ABCB1—myometrium—uterine cancer	7.75e-05	0.00883	CbGeAlD
Norethindrone—CYP3A5—female gonad—uterine cancer	7.74e-05	0.00882	CbGeAlD
Norethindrone—CYP3A5—vagina—uterine cancer	7.7e-05	0.00876	CbGeAlD
Norethindrone—Breast disorder—Medroxyprogesterone Acetate—uterine cancer	7.62e-05	0.00185	CcSEcCtD
Norethindrone—Abdominal distension—Medroxyprogesterone Acetate—uterine cancer	7.33e-05	0.00178	CcSEcCtD
Norethindrone—Weight increased—Progesterone—uterine cancer	7.32e-05	0.00177	CcSEcCtD
Norethindrone—Norgestimate—PGR—uterine cancer	7.25e-05	0.051	CrCbGaD
Norethindrone—Drowsiness—Progesterone—uterine cancer	7.17e-05	0.00174	CcSEcCtD
Norethindrone—Depression—Progesterone—uterine cancer	7.15e-05	0.00173	CcSEcCtD
Norethindrone—Hepatobiliary disease—Progesterone—uterine cancer	6.78e-05	0.00164	CcSEcCtD
Norethindrone—Danazol—CCL2—uterine cancer	6.64e-05	0.0467	CrCbGaD
Norethindrone—Blindness—Epirubicin—uterine cancer	6.64e-05	0.00161	CcSEcCtD
Norethindrone—Weight increased—Medroxyprogesterone Acetate—uterine cancer	6.63e-05	0.00161	CcSEcCtD
Norethindrone—Quinestrol—ESR1—uterine cancer	6.54e-05	0.0459	CrCbGaD
Norethindrone—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	6.5e-05	0.00157	CcSEcCtD
Norethindrone—Depression—Medroxyprogesterone Acetate—uterine cancer	6.48e-05	0.00157	CcSEcCtD
Norethindrone—Haemoglobin—Progesterone—uterine cancer	6.47e-05	0.00157	CcSEcCtD
Norethindrone—Haemorrhage—Progesterone—uterine cancer	6.44e-05	0.00156	CcSEcCtD
Norethindrone—Hepatitis—Progesterone—uterine cancer	6.44e-05	0.00156	CcSEcCtD
Norethindrone—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	6.4e-05	0.00155	CcSEcCtD
Norethindrone—CYP3A4—female reproductive system—uterine cancer	6.39e-05	0.00727	CbGeAlD
Norethindrone—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	6.37e-05	0.00154	CcSEcCtD
Norethindrone—Connective tissue disorder—Progesterone—uterine cancer	6.32e-05	0.00153	CcSEcCtD
Norethindrone—Etonogestrel—PGR—uterine cancer	6.28e-05	0.0441	CrCbGaD
Norethindrone—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	6.14e-05	0.00149	CcSEcCtD
Norethindrone—Blindness—Doxorubicin—uterine cancer	6.14e-05	0.00149	CcSEcCtD
Norethindrone—ABCB1—epithelium—uterine cancer	6.09e-05	0.00693	CbGeAlD
Norethindrone—Erythema multiforme—Progesterone—uterine cancer	6.09e-05	0.00147	CcSEcCtD
Norethindrone—Nandrolone phenpropionate—CYP19A1—uterine cancer	6.04e-05	0.0425	CrCbGaD
Norethindrone—ABCB1—uterine cervix—uterine cancer	6.03e-05	0.00687	CbGeAlD
Norethindrone—Optic neuritis—Epirubicin—uterine cancer	5.97e-05	0.00145	CcSEcCtD
Norethindrone—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	5.86e-05	0.00142	CcSEcCtD
Norethindrone—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	5.83e-05	0.00141	CcSEcCtD
Norethindrone—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	5.83e-05	0.00141	CcSEcCtD
Norethindrone—Immune system disorder—Progesterone—uterine cancer	5.81e-05	0.00141	CcSEcCtD
Norethindrone—ABCB1—decidua—uterine cancer	5.75e-05	0.00655	CbGeAlD
Norethindrone—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	5.73e-05	0.00139	CcSEcCtD
Norethindrone—Embolism—Epirubicin—uterine cancer	5.72e-05	0.00139	CcSEcCtD
Norethindrone—Alopecia—Progesterone—uterine cancer	5.69e-05	0.00138	CcSEcCtD
Norethindrone—ABCB1—renal system—uterine cancer	5.65e-05	0.00643	CbGeAlD
Norethindrone—Mental disorder—Progesterone—uterine cancer	5.64e-05	0.00137	CcSEcCtD
Norethindrone—Optic neuritis—Doxorubicin—uterine cancer	5.53e-05	0.00134	CcSEcCtD
Norethindrone—Flatulence—Progesterone—uterine cancer	5.52e-05	0.00134	CcSEcCtD
Norethindrone—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	5.51e-05	0.00134	CcSEcCtD
Norethindrone—Tension—Progesterone—uterine cancer	5.5e-05	0.00133	CcSEcCtD
Norethindrone—ABCB1—endometrium—uterine cancer	5.46e-05	0.00621	CbGeAlD
Norethindrone—Drospirenone—PGR—uterine cancer	5.44e-05	0.0382	CrCbGaD
Norethindrone—Nervousness—Progesterone—uterine cancer	5.44e-05	0.00132	CcSEcCtD
Norethindrone—Ethynodiol—ESR1—uterine cancer	5.39e-05	0.0378	CrCbGaD
Norethindrone—Embolism—Doxorubicin—uterine cancer	5.3e-05	0.00128	CcSEcCtD
Norethindrone—ABCB1—mammalian vulva—uterine cancer	5.28e-05	0.00601	CbGeAlD
Norethindrone—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	5.27e-05	0.00128	CcSEcCtD
Norethindrone—Thrombosis—Epirubicin—uterine cancer	5.19e-05	0.00126	CcSEcCtD
Norethindrone—Alopecia—Medroxyprogesterone Acetate—uterine cancer	5.15e-05	0.00125	CcSEcCtD
Norethindrone—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	5.11e-05	0.00124	CcSEcCtD
Norethindrone—Allylestrenol—ESR1—uterine cancer	5.09e-05	0.0357	CrCbGaD
Norethindrone—ABCB1—uterus—uterine cancer	5.03e-05	0.00573	CbGeAlD
Norethindrone—Flatulence—Medroxyprogesterone Acetate—uterine cancer	5e-05	0.00121	CcSEcCtD
Norethindrone—Tension—Medroxyprogesterone Acetate—uterine cancer	4.98e-05	0.00121	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Epirubicin—uterine cancer	4.97e-05	0.0012	CcSEcCtD
Norethindrone—Dermatitis atopic—Epirubicin—uterine cancer	4.97e-05	0.0012	CcSEcCtD
Norethindrone—Mestranol—ESR1—uterine cancer	4.96e-05	0.0348	CrCbGaD
Norethindrone—Nervousness—Medroxyprogesterone Acetate—uterine cancer	4.93e-05	0.00119	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Etoposide—uterine cancer	4.92e-05	0.00119	CcSEcCtD
Norethindrone—Desogestrel—ESR1—uterine cancer	4.9e-05	0.0344	CrCbGaD
Norethindrone—Convulsion—Progesterone—uterine cancer	4.85e-05	0.00118	CcSEcCtD
Norethindrone—Thrombosis—Doxorubicin—uterine cancer	4.8e-05	0.00116	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	4.74e-05	0.00115	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Doxorubicin—uterine cancer	4.59e-05	0.00111	CcSEcCtD
Norethindrone—Dermatitis atopic—Doxorubicin—uterine cancer	4.59e-05	0.00111	CcSEcCtD
Norethindrone—Norgestimate—ESR1—uterine cancer	4.58e-05	0.0322	CrCbGaD
Norethindrone—Nandrolone decanoate—CYP19A1—uterine cancer	4.58e-05	0.0322	CrCbGaD
Norethindrone—Oedema—Progesterone—uterine cancer	4.57e-05	0.00111	CcSEcCtD
Norethindrone—Anaphylactic shock—Progesterone—uterine cancer	4.57e-05	0.00111	CcSEcCtD
Norethindrone—Hepatitis—Dactinomycin—uterine cancer	4.55e-05	0.0011	CcSEcCtD
Norethindrone—ABCB1—female reproductive system—uterine cancer	4.52e-05	0.00515	CbGeAlD
Norethindrone—Skin disorder—Progesterone—uterine cancer	4.44e-05	0.00108	CcSEcCtD
Norethindrone—Levonorgestrel—PGR—uterine cancer	4.44e-05	0.0312	CrCbGaD
Norethindrone—Convulsion—Medroxyprogesterone Acetate—uterine cancer	4.4e-05	0.00107	CcSEcCtD
Norethindrone—Neoplasm malignant—Epirubicin—uterine cancer	4.3e-05	0.00104	CcSEcCtD
Norethindrone—Erythema multiforme—Dactinomycin—uterine cancer	4.3e-05	0.00104	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	4.29e-05	0.00104	CcSEcCtD
Norethindrone—Breast pain—Epirubicin—uterine cancer	4.21e-05	0.00102	CcSEcCtD
Norethindrone—Jaundice cholestatic—Epirubicin—uterine cancer	4.18e-05	0.00101	CcSEcCtD
Norethindrone—Amenorrhoea—Epirubicin—uterine cancer	4.18e-05	0.00101	CcSEcCtD
Norethindrone—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	4.14e-05	0.001	CcSEcCtD
Norethindrone—Oedema—Medroxyprogesterone Acetate—uterine cancer	4.14e-05	0.001	CcSEcCtD
Norethindrone—Insomnia—Progesterone—uterine cancer	4.14e-05	0.001	CcSEcCtD
Norethindrone—ABCB1—female gonad—uterine cancer	4.11e-05	0.00468	CbGeAlD
Norethindrone—ABCB1—vagina—uterine cancer	4.09e-05	0.00466	CbGeAlD
Norethindrone—Somnolence—Progesterone—uterine cancer	4.06e-05	0.000985	CcSEcCtD
Norethindrone—Danazol—PGR—uterine cancer	4.04e-05	0.0284	CrCbGaD
Norethindrone—Dyspepsia—Progesterone—uterine cancer	4.02e-05	0.000975	CcSEcCtD
Norethindrone—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	4.02e-05	0.000975	CcSEcCtD
Norethindrone—Alopecia—Dactinomycin—uterine cancer	4.02e-05	0.000974	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—uterine cancer	3.98e-05	0.000965	CcSEcCtD
Norethindrone—Etonogestrel—ESR1—uterine cancer	3.96e-05	0.0278	CrCbGaD
Norethindrone—Gastrointestinal disorder—Progesterone—uterine cancer	3.95e-05	0.000956	CcSEcCtD
Norethindrone—Fatigue—Progesterone—uterine cancer	3.94e-05	0.000955	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—uterine cancer	3.9e-05	0.000944	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—uterine cancer	3.87e-05	0.000938	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—uterine cancer	3.87e-05	0.000938	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ESR2—uterine cancer	3.83e-05	0.0269	CrCbGaD
Norethindrone—Insomnia—Medroxyprogesterone Acetate—uterine cancer	3.75e-05	0.000908	CcSEcCtD
Norethindrone—Gastrointestinal pain—Progesterone—uterine cancer	3.74e-05	0.000906	CcSEcCtD
Norethindrone—Somnolence—Medroxyprogesterone Acetate—uterine cancer	3.68e-05	0.000892	CcSEcCtD
Norethindrone—Pulmonary embolism—Epirubicin—uterine cancer	3.68e-05	0.00089	CcSEcCtD
Norethindrone—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	3.65e-05	0.000884	CcSEcCtD
Norethindrone—Urticaria—Progesterone—uterine cancer	3.63e-05	0.00088	CcSEcCtD
Norethindrone—Acute coronary syndrome—Etoposide—uterine cancer	3.62e-05	0.000876	CcSEcCtD
Norethindrone—Abdominal pain—Progesterone—uterine cancer	3.61e-05	0.000876	CcSEcCtD
Norethindrone—Renal failure—Etoposide—uterine cancer	3.61e-05	0.000873	CcSEcCtD
Norethindrone—Myocardial infarction—Etoposide—uterine cancer	3.59e-05	0.000871	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	3.58e-05	0.000867	CcSEcCtD
Norethindrone—Fatigue—Medroxyprogesterone Acetate—uterine cancer	3.57e-05	0.000865	CcSEcCtD
Norethindrone—Hepatobiliary disease—Etoposide—uterine cancer	3.47e-05	0.00084	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—uterine cancer	3.4e-05	0.000824	CcSEcCtD
Norethindrone—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	3.39e-05	0.000821	CcSEcCtD
Norethindrone—Hypersensitivity—Progesterone—uterine cancer	3.37e-05	0.000816	CcSEcCtD
Norethindrone—Urticaria—Medroxyprogesterone Acetate—uterine cancer	3.29e-05	0.000797	CcSEcCtD
Norethindrone—Asthenia—Progesterone—uterine cancer	3.28e-05	0.000795	CcSEcCtD
Norethindrone—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	3.28e-05	0.000793	CcSEcCtD
Norethindrone—Pruritus—Progesterone—uterine cancer	3.23e-05	0.000784	CcSEcCtD
Norethindrone—Oedema—Dactinomycin—uterine cancer	3.23e-05	0.000783	CcSEcCtD
Norethindrone—Erythema multiforme—Etoposide—uterine cancer	3.11e-05	0.000754	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—uterine cancer	3.08e-05	0.000747	CcSEcCtD
Norethindrone—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	3.05e-05	0.00074	CcSEcCtD
Norethindrone—Levonorgestrel—CYP19A1—uterine cancer	3.05e-05	0.0214	CrCbGaD
Norethindrone—Photosensitivity—Epirubicin—uterine cancer	3.04e-05	0.000736	CcSEcCtD
Norethindrone—Dizziness—Progesterone—uterine cancer	3.02e-05	0.000733	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—uterine cancer	2.97e-05	0.00072	CcSEcCtD
Norethindrone—Asthenia—Medroxyprogesterone Acetate—uterine cancer	2.97e-05	0.00072	CcSEcCtD
Norethindrone—Pruritus—Medroxyprogesterone Acetate—uterine cancer	2.93e-05	0.00071	CcSEcCtD
Norethindrone—Alopecia—Etoposide—uterine cancer	2.91e-05	0.000705	CcSEcCtD
Norethindrone—Vomiting—Progesterone—uterine cancer	2.91e-05	0.000704	CcSEcCtD
Norethindrone—Rash—Progesterone—uterine cancer	2.88e-05	0.000698	CcSEcCtD
Norethindrone—Dermatitis—Progesterone—uterine cancer	2.88e-05	0.000698	CcSEcCtD
Norethindrone—Headache—Progesterone—uterine cancer	2.86e-05	0.000694	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—uterine cancer	2.85e-05	0.000691	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—uterine cancer	2.81e-05	0.000681	CcSEcCtD
Norethindrone—Levonorgestrel—ESR1—uterine cancer	2.8e-05	0.0197	CrCbGaD
Norethindrone—Renal impairment—Epirubicin—uterine cancer	2.8e-05	0.000679	CcSEcCtD
Norethindrone—Fatigue—Dactinomycin—uterine cancer	2.79e-05	0.000675	CcSEcCtD
Norethindrone—Danazol—CYP19A1—uterine cancer	2.77e-05	0.0195	CrCbGaD
Norethindrone—Purpura—Epirubicin—uterine cancer	2.77e-05	0.000671	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—uterine cancer	2.76e-05	0.000668	CcSEcCtD
Norethindrone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	2.74e-05	0.000664	CcSEcCtD
Norethindrone—Nausea—Progesterone—uterine cancer	2.72e-05	0.000658	CcSEcCtD
Norethindrone—Fluoxymesterone—ESR1—uterine cancer	2.67e-05	0.0188	CrCbGaD
Norethindrone—Pain in extremity—Epirubicin—uterine cancer	2.67e-05	0.000646	CcSEcCtD
Norethindrone—ABCB1—lymph node—uterine cancer	2.64e-05	0.00301	CbGeAlD
Norethindrone—Gastrointestinal pain—Dactinomycin—uterine cancer	2.64e-05	0.00064	CcSEcCtD
Norethindrone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	2.63e-05	0.000638	CcSEcCtD
Norethindrone—Testosterone—CYP11A1—uterine cancer	2.63e-05	0.0185	CrCbGaD
Norethindrone—Affect lability—Epirubicin—uterine cancer	2.63e-05	0.000636	CcSEcCtD
Norethindrone—Migraine—Epirubicin—uterine cancer	2.63e-05	0.000636	CcSEcCtD
Norethindrone—Rash—Medroxyprogesterone Acetate—uterine cancer	2.61e-05	0.000633	CcSEcCtD
Norethindrone—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	2.61e-05	0.000632	CcSEcCtD
Norethindrone—Headache—Medroxyprogesterone Acetate—uterine cancer	2.6e-05	0.000629	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—uterine cancer	2.59e-05	0.000628	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—uterine cancer	2.56e-05	0.00062	CcSEcCtD
Norethindrone—Abdominal pain—Dactinomycin—uterine cancer	2.55e-05	0.000619	CcSEcCtD
Norethindrone—Danazol—ESR1—uterine cancer	2.55e-05	0.0179	CrCbGaD
Norethindrone—Anaphylactoid reaction—Doxorubicin—uterine cancer	2.55e-05	0.000618	CcSEcCtD
Norethindrone—Mood swings—Epirubicin—uterine cancer	2.53e-05	0.000612	CcSEcCtD
Norethindrone—Convulsion—Etoposide—uterine cancer	2.48e-05	0.000602	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—uterine cancer	2.47e-05	0.000598	CcSEcCtD
Norethindrone—Nausea—Medroxyprogesterone Acetate—uterine cancer	2.46e-05	0.000596	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—uterine cancer	2.43e-05	0.000589	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—uterine cancer	2.43e-05	0.000589	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	2.42e-05	0.000587	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—uterine cancer	2.41e-05	0.000584	CcSEcCtD
Norethindrone—Hypersensitivity—Dactinomycin—uterine cancer	2.38e-05	0.000577	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ESR1—uterine cancer	2.36e-05	0.0166	CrCbGaD
Norethindrone—Methyltestosterone—CYP19A1—uterine cancer	2.34e-05	0.0165	CrCbGaD
Norethindrone—Anaphylactic shock—Etoposide—uterine cancer	2.34e-05	0.000567	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—uterine cancer	2.34e-05	0.000566	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—uterine cancer	2.32e-05	0.000562	CcSEcCtD
Norethindrone—Asthenia—Dactinomycin—uterine cancer	2.32e-05	0.000562	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—uterine cancer	2.27e-05	0.00055	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—uterine cancer	2.23e-05	0.00054	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—uterine cancer	2.15e-05	0.00052	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—uterine cancer	2.1e-05	0.00051	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—uterine cancer	2.1e-05	0.000508	CcSEcCtD
Norethindrone—Progesterone—PGR—uterine cancer	2.1e-05	0.0147	CrCbGaD
Norethindrone—Somnolence—Etoposide—uterine cancer	2.08e-05	0.000504	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—uterine cancer	2.06e-05	0.000498	CcSEcCtD
Norethindrone—Vomiting—Dactinomycin—uterine cancer	2.05e-05	0.000498	CcSEcCtD
Norethindrone—Rash—Dactinomycin—uterine cancer	2.04e-05	0.000494	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—uterine cancer	2.02e-05	0.00049	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—uterine cancer	2.02e-05	0.000489	CcSEcCtD
Norethindrone—Fatigue—Etoposide—uterine cancer	2.02e-05	0.000489	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—uterine cancer	1.95e-05	0.000472	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—uterine cancer	1.94e-05	0.000471	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—uterine cancer	1.94e-05	0.00047	CcSEcCtD
Norethindrone—Nausea—Dactinomycin—uterine cancer	1.92e-05	0.000465	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—uterine cancer	1.91e-05	0.000463	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—uterine cancer	1.9e-05	0.000461	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—uterine cancer	1.87e-05	0.000453	CcSEcCtD
Norethindrone—Urticaria—Etoposide—uterine cancer	1.86e-05	0.00045	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—uterine cancer	1.85e-05	0.000449	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—uterine cancer	1.85e-05	0.000448	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—uterine cancer	1.85e-05	0.000447	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—uterine cancer	1.85e-05	0.000447	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—uterine cancer	1.81e-05	0.000439	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—uterine cancer	1.8e-05	0.000436	CcSEcCtD
Norethindrone—Erythema multiforme—Epirubicin—uterine cancer	1.74e-05	0.000423	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—uterine cancer	1.72e-05	0.000417	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—uterine cancer	1.72e-05	0.000416	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—uterine cancer	1.71e-05	0.000414	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—uterine cancer	1.71e-05	0.000414	CcSEcCtD
Norethindrone—Asthenia—Etoposide—uterine cancer	1.68e-05	0.000407	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—uterine cancer	1.68e-05	0.000407	CcSEcCtD
Norethindrone—Immune system disorder—Epirubicin—uterine cancer	1.67e-05	0.000404	CcSEcCtD
Norethindrone—Pruritus—Etoposide—uterine cancer	1.65e-05	0.000401	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—uterine cancer	1.63e-05	0.000395	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—uterine cancer	1.62e-05	0.000392	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—uterine cancer	1.61e-05	0.000391	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—uterine cancer	1.58e-05	0.000384	CcSEcCtD
Norethindrone—Tension—Epirubicin—uterine cancer	1.58e-05	0.000382	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—uterine cancer	1.56e-05	0.000378	CcSEcCtD
Norethindrone—Dizziness—Etoposide—uterine cancer	1.55e-05	0.000375	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—uterine cancer	1.54e-05	0.000374	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—uterine cancer	1.51e-05	0.000366	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—uterine cancer	1.5e-05	0.000362	CcSEcCtD
Norethindrone—Vomiting—Etoposide—uterine cancer	1.49e-05	0.00036	CcSEcCtD
Norethindrone—Rash—Etoposide—uterine cancer	1.47e-05	0.000357	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—uterine cancer	1.47e-05	0.000357	CcSEcCtD
Norethindrone—Headache—Etoposide—uterine cancer	1.47e-05	0.000355	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—uterine cancer	1.46e-05	0.000355	CcSEcCtD
Norethindrone—Tension—Doxorubicin—uterine cancer	1.46e-05	0.000353	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—uterine cancer	1.44e-05	0.00035	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—uterine cancer	1.39e-05	0.000337	CcSEcCtD
Norethindrone—Nausea—Etoposide—uterine cancer	1.39e-05	0.000337	CcSEcCtD
Norethindrone—Testosterone—CYP19A1—uterine cancer	1.36e-05	0.00955	CrCbGaD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	1.36e-05	0.000329	CcSEcCtD
Norethindrone—Progesterone—ESR1—uterine cancer	1.32e-05	0.0093	CrCbGaD
Norethindrone—Oedema—Epirubicin—uterine cancer	1.31e-05	0.000318	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—uterine cancer	1.31e-05	0.000318	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—uterine cancer	1.29e-05	0.000312	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—uterine cancer	1.27e-05	0.000309	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	1.26e-05	0.000304	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—uterine cancer	1.21e-05	0.000294	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—uterine cancer	1.21e-05	0.000294	CcSEcCtD
Norethindrone—Insomnia—Epirubicin—uterine cancer	1.19e-05	0.000287	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—uterine cancer	1.18e-05	0.000285	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—uterine cancer	1.17e-05	0.000282	CcSEcCtD
Norethindrone—Dyspepsia—Epirubicin—uterine cancer	1.15e-05	0.00028	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—uterine cancer	1.13e-05	0.000274	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—uterine cancer	1.13e-05	0.000274	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—uterine cancer	1.1e-05	0.000266	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—uterine cancer	1.08e-05	0.000261	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—uterine cancer	1.07e-05	0.00026	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—uterine cancer	1.07e-05	0.000259	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—uterine cancer	1.05e-05	0.000254	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—uterine cancer	1.05e-05	0.000253	CcSEcCtD
Norethindrone—Urticaria—Epirubicin—uterine cancer	1.04e-05	0.000252	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—uterine cancer	1.04e-05	0.000251	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—uterine cancer	9.92e-06	0.00024	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—uterine cancer	9.66e-06	0.000234	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—uterine cancer	9.64e-06	0.000233	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—uterine cancer	9.59e-06	0.000232	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—uterine cancer	9.41e-06	0.000228	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—uterine cancer	9.28e-06	0.000225	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—uterine cancer	8.94e-06	0.000217	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—uterine cancer	8.7e-06	0.000211	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—uterine cancer	8.67e-06	0.00021	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—uterine cancer	8.58e-06	0.000208	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—uterine cancer	8.34e-06	0.000202	CcSEcCtD
Norethindrone—Rash—Epirubicin—uterine cancer	8.27e-06	0.0002	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—uterine cancer	8.26e-06	0.0002	CcSEcCtD
Norethindrone—Headache—Epirubicin—uterine cancer	8.21e-06	0.000199	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—uterine cancer	8.02e-06	0.000194	CcSEcCtD
Norethindrone—Nausea—Epirubicin—uterine cancer	7.79e-06	0.000189	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—uterine cancer	7.71e-06	0.000187	CcSEcCtD
Norethindrone—Rash—Doxorubicin—uterine cancer	7.65e-06	0.000185	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—uterine cancer	7.64e-06	0.000185	CcSEcCtD
Norethindrone—Headache—Doxorubicin—uterine cancer	7.6e-06	0.000184	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—uterine cancer	7.21e-06	0.000175	CcSEcCtD
Norethindrone—ALB—Vitamin B12 Metabolism—MTHFR—uterine cancer	6.17e-06	0.00506	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—AKR1C1—uterine cancer	5.93e-06	0.00487	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—CHD4—uterine cancer	5.78e-06	0.00474	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	5.29e-06	0.00434	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.25e-06	0.00431	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	5.22e-06	0.00429	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—GPX3—uterine cancer	5.21e-06	0.00427	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—MTHFR—uterine cancer	5.02e-06	0.00412	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP19A1—uterine cancer	4.99e-06	0.00409	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP19A1—uterine cancer	4.92e-06	0.00404	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP11A1—uterine cancer	4.9e-06	0.00402	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—SUZ12—uterine cancer	4.84e-06	0.00397	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	4.83e-06	0.00397	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—CCL2—uterine cancer	4.83e-06	0.00396	CbGpPWpGaD
Norethindrone—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	4.82e-06	0.00395	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	4.79e-06	0.00393	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—ERBB2—uterine cancer	4.74e-06	0.00389	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	4.63e-06	0.0038	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	4.59e-06	0.00376	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	4.57e-06	0.00375	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—ESR2—uterine cancer	4.41e-06	0.00362	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—CDKN1B—uterine cancer	4.39e-06	0.0036	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.29e-06	0.00352	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—PTEN—uterine cancer	4.04e-06	0.00332	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	4.04e-06	0.00332	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	4.03e-06	0.0033	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—MTHFR—uterine cancer	3.99e-06	0.00327	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—CCL2—uterine cancer	3.93e-06	0.00322	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	3.89e-06	0.00319	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	3.84e-06	0.00315	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	3.79e-06	0.00311	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	3.76e-06	0.00308	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.75e-06	0.00307	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	3.74e-06	0.00307	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—NRAS—uterine cancer	3.61e-06	0.00296	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	3.61e-06	0.00296	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—CDKN2B—uterine cancer	3.59e-06	0.00294	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	3.56e-06	0.00292	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	3.53e-06	0.0029	CbGpPWpGaD
Norethindrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	3.37e-06	0.00277	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.36e-06	0.00276	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—SMAD3—uterine cancer	3.28e-06	0.00269	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.16e-06	0.00259	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—CCL2—uterine cancer	3.12e-06	0.00256	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—KRAS—uterine cancer	3.11e-06	0.00255	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKR1B10—uterine cancer	3.06e-06	0.00251	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	2.97e-06	0.00244	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—PIK3CA—uterine cancer	2.85e-06	0.00234	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	2.79e-06	0.00229	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	2.76e-06	0.00226	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	2.76e-06	0.00226	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	2.75e-06	0.00226	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.71e-06	0.00222	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.71e-06	0.00222	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—SRD5A2—uterine cancer	2.68e-06	0.0022	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NDUFB11—uterine cancer	2.68e-06	0.0022	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—ESR1—uterine cancer	2.67e-06	0.00219	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—HRAS—uterine cancer	2.64e-06	0.00217	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—ABCC9—uterine cancer	2.58e-06	0.00211	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RNF43—uterine cancer	2.54e-06	0.00208	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	2.5e-06	0.00205	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.43e-06	0.002	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.43e-06	0.002	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.42e-06	0.00199	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CXCL8—uterine cancer	2.36e-06	0.00193	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	2.33e-06	0.00192	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—AKT1—uterine cancer	2.33e-06	0.00191	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—INHBA—uterine cancer	2.32e-06	0.0019	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—EZH2—uterine cancer	2.29e-06	0.00188	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.28e-06	0.00187	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	2.26e-06	0.00185	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.25e-06	0.00184	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	2.24e-06	0.00184	CbGpPWpGaD
Norethindrone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	2.23e-06	0.00183	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	2.21e-06	0.00181	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—VEGFA—uterine cancer	2.16e-06	0.00178	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR2—uterine cancer	2.12e-06	0.00174	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.12e-06	0.00174	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKR1C1—uterine cancer	2.09e-06	0.00171	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	2.06e-06	0.00169	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.99e-06	0.00163	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKR1B1—uterine cancer	1.94e-06	0.00159	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—STAR—uterine cancer	1.94e-06	0.00159	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NDUFB11—uterine cancer	1.94e-06	0.00159	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—SRD5A2—uterine cancer	1.94e-06	0.00159	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—VEGFA—uterine cancer	1.91e-06	0.00157	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—uterine cancer	1.91e-06	0.00156	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.79e-06	0.00146	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—CDKN2B—uterine cancer	1.73e-06	0.00142	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.68e-06	0.00138	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IRF1—uterine cancer	1.67e-06	0.00137	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	1.67e-06	0.00137	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NDUFB11—uterine cancer	1.67e-06	0.00137	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SRD5A2—uterine cancer	1.67e-06	0.00137	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.65e-06	0.00136	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.62e-06	0.00133	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKR1C3—uterine cancer	1.61e-06	0.00132	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—SMAD3—uterine cancer	1.58e-06	0.00129	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.53e-06	0.00126	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—POLD1—uterine cancer	1.52e-06	0.00125	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.5e-06	0.00123	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.5e-06	0.00123	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—YWHAE—uterine cancer	1.5e-06	0.00123	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SRD5A2—uterine cancer	1.46e-06	0.0012	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NDUFB11—uterine cancer	1.46e-06	0.0012	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.46e-06	0.00119	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—FBXW7—uterine cancer	1.43e-06	0.00118	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKR1C1—uterine cancer	1.42e-06	0.00117	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	1.41e-06	0.00116	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—STAR—uterine cancer	1.4e-06	0.00115	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKR1B1—uterine cancer	1.4e-06	0.00115	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.37e-06	0.00113	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR1—uterine cancer	1.29e-06	0.00106	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—RRM2—uterine cancer	1.27e-06	0.00104	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STK11—uterine cancer	1.25e-06	0.00103	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—DCN—uterine cancer	1.23e-06	0.00101	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.23e-06	0.00101	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKR1B1—uterine cancer	1.21e-06	0.00099	CbGpPWpGaD
Norethindrone—ALB—Metabolism—STAR—uterine cancer	1.21e-06	0.00099	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.19e-06	0.000979	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SOCS3—uterine cancer	1.17e-06	0.000963	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP11A1—uterine cancer	1.16e-06	0.000952	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.14e-06	0.000932	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN2B—uterine cancer	1.12e-06	0.000922	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—POLD1—uterine cancer	1.1e-06	0.000902	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKR1C3—uterine cancer	1.1e-06	0.000899	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IGF1R—uterine cancer	1.09e-06	0.000895	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.08e-06	0.000889	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—STAR—uterine cancer	1.08e-06	0.000889	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.07e-06	0.000881	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.07e-06	0.000878	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—STAR—uterine cancer	1.06e-06	0.000867	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKR1B1—uterine cancer	1.06e-06	0.000867	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.05e-06	0.000858	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.03e-06	0.000844	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SMAD3—uterine cancer	1.03e-06	0.000842	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.98e-07	0.000819	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—FGFR2—uterine cancer	9.78e-07	0.000803	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	9.6e-07	0.000787	CbGpPWpGaD
Norethindrone—ALB—Metabolism—POLD1—uterine cancer	9.47e-07	0.000777	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	9.45e-07	0.000775	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—RRM2—uterine cancer	9.17e-07	0.000752	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NDUFB11—uterine cancer	9.01e-07	0.000739	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SRD5A2—uterine cancer	9.01e-07	0.000739	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—DCN—uterine cancer	8.9e-07	0.00073	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKR1C1—uterine cancer	8.86e-07	0.000727	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—STK11—uterine cancer	8.53e-07	0.0007	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP19A1—uterine cancer	8.53e-07	0.0007	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—POLD1—uterine cancer	8.5e-07	0.000697	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP11A1—uterine cancer	8.38e-07	0.000688	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ESR1—uterine cancer	8.37e-07	0.000687	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—POLD1—uterine cancer	8.3e-07	0.000681	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.03e-07	0.000659	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKR1C1—uterine cancer	7.95e-07	0.000652	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKR1C3—uterine cancer	7.92e-07	0.00065	CbGpPWpGaD
Norethindrone—ALB—Metabolism—RRM2—uterine cancer	7.89e-07	0.000648	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKR1C1—uterine cancer	7.76e-07	0.000637	CbGpPWpGaD
Norethindrone—ALB—Metabolism—DCN—uterine cancer	7.66e-07	0.000629	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	7.5e-07	0.000615	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.38e-07	0.000606	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCL2—uterine cancer	7.37e-07	0.000605	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP11A1—uterine cancer	7.22e-07	0.000592	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.14e-07	0.000586	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—RRM2—uterine cancer	7.09e-07	0.000581	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—RRM2—uterine cancer	6.92e-07	0.000567	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—DCN—uterine cancer	6.88e-07	0.000564	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKR1C3—uterine cancer	6.82e-07	0.000559	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—DCN—uterine cancer	6.71e-07	0.000551	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—STAR—uterine cancer	6.51e-07	0.000534	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKR1B1—uterine cancer	6.51e-07	0.000534	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP11A1—uterine cancer	6.48e-07	0.000532	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—MTHFR—uterine cancer	6.41e-07	0.000526	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP11A1—uterine cancer	6.33e-07	0.000519	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP19A1—uterine cancer	6.17e-07	0.000506	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—STK11—uterine cancer	6.17e-07	0.000506	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB2—uterine cancer	6.14e-07	0.000504	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	6.12e-07	0.000502	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKR1C3—uterine cancer	6.12e-07	0.000502	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.03e-07	0.000495	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKR1C3—uterine cancer	5.97e-07	0.00049	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—uterine cancer	5.83e-07	0.000478	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1B—uterine cancer	5.69e-07	0.000467	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CTNNB1—uterine cancer	5.38e-07	0.000441	CbGpPWpGaD
Norethindrone—ALB—Metabolism—STK11—uterine cancer	5.31e-07	0.000436	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP19A1—uterine cancer	5.31e-07	0.000436	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTEN—uterine cancer	5.24e-07	0.00043	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—EP300—uterine cancer	5.22e-07	0.000429	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—POLD1—uterine cancer	5.11e-07	0.000419	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EP300—uterine cancer	5e-07	0.00041	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.99e-07	0.000409	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—uterine cancer	4.95e-07	0.000406	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NRAS—uterine cancer	4.89e-07	0.000401	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKR1C1—uterine cancer	4.78e-07	0.000392	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—STK11—uterine cancer	4.77e-07	0.000391	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP19A1—uterine cancer	4.77e-07	0.000391	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.76e-07	0.00039	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—uterine cancer	4.73e-07	0.000388	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NRAS—uterine cancer	4.67e-07	0.000383	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—STK11—uterine cancer	4.65e-07	0.000382	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP19A1—uterine cancer	4.65e-07	0.000382	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—AKT1—uterine cancer	4.64e-07	0.000381	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—MTHFR—uterine cancer	4.63e-07	0.00038	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.48e-07	0.000367	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.27e-07	0.00035	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RRM2—uterine cancer	4.26e-07	0.00035	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—KRAS—uterine cancer	4.21e-07	0.000345	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—DCN—uterine cancer	4.14e-07	0.000339	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KRAS—uterine cancer	4.02e-07	0.00033	CbGpPWpGaD
Norethindrone—ALB—Metabolism—MTHFR—uterine cancer	3.99e-07	0.000327	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP11A1—uterine cancer	3.9e-07	0.00032	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CA—uterine cancer	3.86e-07	0.000317	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—uterine cancer	3.74e-07	0.000307	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CA—uterine cancer	3.7e-07	0.000303	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.68e-07	0.000302	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—MTHFR—uterine cancer	3.58e-07	0.000294	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—uterine cancer	3.58e-07	0.000293	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—HRAS—uterine cancer	3.57e-07	0.000293	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTEN—uterine cancer	3.57e-07	0.000293	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.52e-07	0.000289	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—MTHFR—uterine cancer	3.5e-07	0.000287	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HRAS—uterine cancer	3.42e-07	0.000281	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—EP300—uterine cancer	3.4e-07	0.000279	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.16e-07	0.000259	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—AKT1—uterine cancer	3.16e-07	0.000259	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKT1—uterine cancer	3.02e-07	0.000248	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.87e-07	0.000235	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—STK11—uterine cancer	2.87e-07	0.000235	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTEN—uterine cancer	2.58e-07	0.000212	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CA—uterine cancer	2.52e-07	0.000206	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—EP300—uterine cancer	2.46e-07	0.000202	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTEN—uterine cancer	2.22e-07	0.000182	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—MTHFR—uterine cancer	2.15e-07	0.000177	CbGpPWpGaD
Norethindrone—ALB—Metabolism—EP300—uterine cancer	2.12e-07	0.000174	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKT1—uterine cancer	2.06e-07	0.000169	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTEN—uterine cancer	1.99e-07	0.000164	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTEN—uterine cancer	1.95e-07	0.00016	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—EP300—uterine cancer	1.9e-07	0.000156	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—EP300—uterine cancer	1.86e-07	0.000152	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.82e-07	0.000149	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CA—uterine cancer	1.57e-07	0.000129	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKT1—uterine cancer	1.49e-07	0.000122	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.41e-07	0.000115	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CA—uterine cancer	1.37e-07	0.000113	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKT1—uterine cancer	1.28e-07	0.000105	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTEN—uterine cancer	1.2e-07	9.83e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKT1—uterine cancer	1.15e-07	9.43e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—EP300—uterine cancer	1.14e-07	9.38e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKT1—uterine cancer	1.12e-07	9.2e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CA—uterine cancer	8.46e-08	6.94e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKT1—uterine cancer	6.91e-08	5.67e-05	CbGpPWpGaD
